8th May 2018

First patient randomized in the PCombi study with Estetrol in patients with prostate cancer.

On 3 May 2018 the first patient has been randomized in the phase IIA clinical study assessing efficacy and safety of the fetal estrogen estetrol (E4) in prostate cancer patients. The study is a double blind, randomised, placebo-controlled multi-center study in prostate cancer patients treated with an LHRH agonist. In total 60 patients will be enrolled at eight centers in the Netherlands. The main objectives of this study are to evaluate the additional effect of […]
5th April 2018

ISGE, March 7-10, 2018, Florence, Italy

On March 8, 2018 Pantarhei Bioscience participated in a scientific symposium entitled Estetrol and Breast Cancer. The lectures were presented by Richard J. Santen (Estetrol in animal in vivo studies), Risto Erkkola (Estetrol in ex vivo explant cultures of human breast cancer tissue) and Herjan Coelingh Bennink (Estetrol treatment of advanced breast cancer). The symposium was chaired by Ludwig Kiesel and Herjan Coelingh Bennink.  
10th November 2017

25th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) November 30- December 2, 2017, Vienna, Austria

On Friday December 1, 2017, the CEO of Pantarhei Herjan Coelingh Bennink¬†lectured during the session: Breast cancer risk from hormonal treatment. The title of the lecture qualified by the organisers as countercurrent was: “Estrogens protect against breast cancer and can be used in selected cases for the treatment of breast cancer”. For more information please read the abstract: Abstract COGI Estrogens and Breast Cancer
10th November 2017

First patient enrolled in clinical study with the fetal estrogen estetrol (E4) in patients with advanced breast cancer (the ABCE4 study)

The first patient has been enrolled in the Phase I/II clinical trial assessing safety and efficacy of estetrol (E4) in postmenopausal women with advanced ER+ breast cancer. The study is a multi-center, open-label, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of E4 for the treatment of patients with advanced breast cancer. In total 9-18 patients will be enrolled at three centers in Germany. The main objectives of this […]